Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of CDB-2914 for preventing pregnancy when taken 3 to 5 days after unprotected sexual intercourse.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00411684
Study type Interventional
Source HRA Pharma
Contact
Status Completed
Phase Phase 3
Start date November 2006
Completion date June 5, 2009

See also
  Status Clinical Trial Phase
Completed NCT00271583 - Efficacy Trial of CDB 2914 for Emergency Contraception Phase 2/Phase 3
Completed NCT00777556 - Emergency Contraception Actual Use Study Phase 3
Completed NCT00677755 - Medical Abortion for Emergency Contraception Failure N/A
Recruiting NCT06162611 - Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo Phase 4
Completed NCT01569737 - Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
Completed NCT03208985 - A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions Phase 3
Completed NCT02078414 - Continued Use of Effective Contraception After Use of Emergency Contraception
Completed NCT01569113 - Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo. Phase 4
Completed NCT01963962 - Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception N/A
Recruiting NCT03120728 - Application for the Etonogestrel/Ethinyl Estradiol Ring Phase 4
Active, not recruiting NCT02076217 - Quick Start of Highly Effective Contraception
Not yet recruiting NCT04172584 - Awareness & Use of Emergency Contraception
Completed NCT03395756 - Depot Medroxyprogesterone Acetate as Emergency Contraception Early Phase 1
Completed NCT03614494 - Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception Phase 2/Phase 3